MA30500B1 - Imidazolones et triazolones d'aryle substitues comme inhibiteurs des recepteurs de vasopressine. - Google Patents
Imidazolones et triazolones d'aryle substitues comme inhibiteurs des recepteurs de vasopressine.Info
- Publication number
- MA30500B1 MA30500B1 MA31452A MA31452A MA30500B1 MA 30500 B1 MA30500 B1 MA 30500B1 MA 31452 A MA31452 A MA 31452A MA 31452 A MA31452 A MA 31452A MA 30500 B1 MA30500 B1 MA 30500B1
- Authority
- MA
- Morocco
- Prior art keywords
- docetaxel
- present
- injection
- water
- hpmc
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 8
- 229960003668 docetaxel Drugs 0.000 abstract 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 6
- 239000002202 Polyethylene glycol Substances 0.000 abstract 4
- 238000002347 injection Methods 0.000 abstract 4
- 239000007924 injection Substances 0.000 abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 abstract 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229920003169 water-soluble polymer Polymers 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 238000003860 storage Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Divulgation de l'invention Problème technique Les présents inventeurs ont réalisé la présente invention en élaborant une composition pharmaceutique pour injection, contenant du docétaxel, qui présente une solubilité et une stabilité améliorées par comparaison avec celles des agents classiques, en combinant du docétaxel hydro-insoluble avec de l'hydroxypropyl-ß-cyclodextrine et un polymère hydrosoluble tel que l'hydroxypropyl méthylcellulose (HPMC), le polyéthylène glycol (PEG) ou la polyvinylpyrrolidone (PVP) dans de l'eau distillée pour améliorer la stabilité du docétaxel dans une solution aqueuse. Par conséquent, il est un objectif de la présente invention de proposer une composition pharmaceutique stable pour injection contenant du docétaxel et un procédé de sa préparation. Solution technique La présente invention se rapporte à une composition pharmaceutique pour injection contenant du docétaxel et présentant une stabilité au stockage supérieure comprenant du docétaxel, de la cyclodextrine et un polymère hydrosoluble tel que l'hydroxypropyl méthylcellulose (HPMC), le polyéthylène glycol (PEG) ou la polyvinylpyrrolidone (PVP). La présente invention concerne également un procédé de préparation d'une composition pharmaceutique pour injection contenant du docétaxel et présentant une stabilité au stockage supérieure, consistant à: 1) mélanger et dissoudre du docétaxel avec de la cyclodextrine et un polymère hydrosoluble choisi à partir d'hydroxypropyl méthylcellulose (HPMC),
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006024024A DE102006024024A1 (de) | 2006-05-23 | 2006-05-23 | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30500B1 true MA30500B1 (fr) | 2009-06-01 |
Family
ID=38353593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31452A MA30500B1 (fr) | 2006-05-23 | 2008-12-05 | Imidazolones et triazolones d'aryle substitues comme inhibiteurs des recepteurs de vasopressine. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8084481B2 (fr) |
| EP (1) | EP2027096B8 (fr) |
| JP (1) | JP5247684B2 (fr) |
| KR (1) | KR101426574B1 (fr) |
| CN (1) | CN101495458B (fr) |
| AR (1) | AR061114A1 (fr) |
| AU (1) | AU2007253572B9 (fr) |
| BR (1) | BRPI0711975A2 (fr) |
| CA (1) | CA2652834C (fr) |
| DE (1) | DE102006024024A1 (fr) |
| DK (1) | DK2027096T3 (fr) |
| DO (1) | DOP2007000102A (fr) |
| EC (1) | ECSP088904A (fr) |
| ES (1) | ES2385606T3 (fr) |
| GT (1) | GT200800250A (fr) |
| HN (1) | HN2008001720A (fr) |
| IL (1) | IL195142A (fr) |
| MA (1) | MA30500B1 (fr) |
| MX (1) | MX2008014797A (fr) |
| PE (1) | PE20080706A1 (fr) |
| PL (1) | PL2027096T3 (fr) |
| PT (1) | PT2027096E (fr) |
| RU (1) | RU2460724C2 (fr) |
| SV (1) | SV2009003098A (fr) |
| TN (1) | TNSN08443A1 (fr) |
| TW (1) | TW200817336A (fr) |
| UY (1) | UY30364A1 (fr) |
| WO (1) | WO2007134862A1 (fr) |
| ZA (1) | ZA200809860B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| EA201170549A1 (ru) * | 2008-10-10 | 2012-01-30 | Янссен Фармацевтика Нв | Комбинированная терапия с использованием блокаторов рецепторов ангиотензина и антагонистов рецепторов вазопрессина |
| DE102008060967A1 (de) * | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
| DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
| DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| DE102009028929A1 (de) * | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| PL2539326T3 (pl) * | 2010-02-27 | 2017-10-31 | Bayer Ip Gmbh | Połączone bis-arylem arylotriazolony i ich zastosowanie |
| EP3593802A3 (fr) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Inhibiteurs de recyclage d'acide biliaire et satiogènes pour le traitement du diabète, de l'obésité et des conditions gastro-intestinales inflammatoires |
| DE102010040187A1 (de) * | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
| DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
| ME02169B (me) | 2010-10-01 | 2015-10-20 | Taisho Pharmaceutical Co Ltd | Derivat 1,2,4-triazolona |
| CN102260154A (zh) * | 2011-06-10 | 2011-11-30 | 南通职业大学 | 一种医药中间体α-溴代对氯苯丙酮的制备方法 |
| CN102875499B (zh) * | 2011-07-12 | 2015-08-19 | 天津药明康德新药开发有限公司 | 3-氨甲基氧杂环丁烷及其有机酸盐的制备方法 |
| EP2736887B1 (fr) * | 2011-07-29 | 2017-10-18 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations |
| CN103889951B (zh) * | 2011-10-27 | 2016-12-14 | 大正制药株式会社 | 唑类衍生物 |
| KR102051031B1 (ko) | 2011-10-28 | 2019-12-02 | 루메나 파마수티컬즈, 인코포레이티드 | 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 |
| BR112014010223B8 (pt) | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica |
| EP2968230A2 (fr) | 2013-03-15 | 2016-01-20 | Lumena Pharmaceuticals, Inc. | Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclérosante primaire et de la maladie inflammatoire de l'intestin |
| KR20160003664A (ko) | 2013-03-15 | 2016-01-11 | 루메나 파마수티컬즈, 인코포레이티드 | 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제 |
| JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
| WO2016010611A1 (fr) * | 2014-07-18 | 2016-01-21 | Ohio University | Procédés et compositions pour modifier l'activité de gsk-3 |
| KR20170081178A (ko) | 2014-11-03 | 2017-07-11 | 바이엘 파마 악티엔게젤샤프트 | 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도 |
| GB201504763D0 (en) * | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| JP6911052B2 (ja) * | 2016-05-03 | 2021-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | オキソアルキル置換フェニルトリアゾール誘導体およびその使用 |
| WO2017191117A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales |
| WO2019141575A1 (fr) | 2018-01-16 | 2019-07-25 | Bayer Aktiengesellschaft | Assistance dans le cadre du traitement de l'insuffisance cardiaque |
| CA3129826A1 (fr) | 2019-02-12 | 2020-08-20 | Mirum Pharmaceuticals, Inc. | Procedes de traitement de la cholestase |
| WO2021127459A1 (fr) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Modulateurs du récepteur gpr139 |
| WO2021252951A1 (fr) | 2020-06-12 | 2021-12-16 | Vanderbilt University | Méthodes de traitement de troubles de motilité gastro-intestinale |
| WO2023041422A1 (fr) | 2021-09-20 | 2023-03-23 | Basf Se | Composés hétérocycliques pour la lutte contre les nuisibles invertébrés |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3042466A1 (de) | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE69024556T2 (de) | 1989-07-28 | 1996-10-17 | Merck & Co Inc | Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten |
| US5468448A (en) * | 1989-12-28 | 1995-11-21 | Ciba-Geigy Corporation | Peroxide disinfection method and devices therefor |
| DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| IT1251488B (it) | 1991-09-17 | 1995-05-15 | Mini Ricerca Scient Tecnolog | Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida |
| RU2116304C1 (ru) * | 1992-04-28 | 1998-07-27 | Такеда Кемикал Индастриз, Лтд. | Производные азола, способ их получения, фармацевтическая композиция |
| SK94393A3 (en) | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| US6844005B2 (en) * | 2002-02-25 | 2005-01-18 | Trutek Corp | Electrostatically charged nasal application product with increased strength |
| FR2708608B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| IL136314A0 (en) | 1997-12-17 | 2001-05-20 | Merck & Co Inc | Integrin receptor antagonists |
| DE19816882A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Triazolone mit neuroprotektiver Wirkung |
| DE19914140A1 (de) * | 1999-03-27 | 2000-09-28 | Bayer Ag | Substituierte Benzoylpyrazole |
| DE19920791A1 (de) * | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
| DE19921424A1 (de) * | 1999-05-08 | 2000-11-09 | Bayer Ag | Substituierte Benzoylketone |
| DE19929348A1 (de) | 1999-06-26 | 2000-12-28 | Bayer Ag | Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten |
| US6531142B1 (en) * | 1999-08-18 | 2003-03-11 | The Procter & Gamble Company | Stable, electrostatically sprayable topical compositions |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| WO2002066447A1 (fr) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | Derives de 4h-1,2,4-triazole-3(2h)-thione tenant lieu d'inhibiteurs de sphingomyelinase |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| US20040071757A1 (en) * | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
| US7192954B2 (en) * | 2003-03-14 | 2007-03-20 | Merck & Co., Inc. | Monocyclic anilide spirohydantoin CGRP receptor antagonists |
| WO2005006892A2 (fr) | 2003-06-27 | 2005-01-27 | Berglin Corporation Of Washington | Machine permettant de noyauter et trancher avec precision et avec une faible contrainte les pommes et autres fruits a coeur tendre ou a noyau |
| NZ585546A (en) | 2003-07-16 | 2011-10-28 | Teva Womens Health Inc | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| JP2007527911A (ja) | 2004-03-08 | 2007-10-04 | ワイス | イオンチャンネルモジュレーター |
| US7547717B2 (en) | 2004-03-08 | 2009-06-16 | Wyeth | Ion channel modulators |
| US20070281937A1 (en) | 2004-03-08 | 2007-12-06 | Robert Zelle | Ion Channel Modulators |
| CA2563963A1 (fr) * | 2004-04-28 | 2005-11-10 | Pfizer Inc. | Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| WO2006117657A1 (fr) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Derives de triazolone utilises comme agents anti-inflammatoires |
| DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| US20080095863A1 (en) * | 2006-10-24 | 2008-04-24 | Alcon Manufacturing Ltd. | 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions |
| DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
-
2006
- 2006-05-23 DE DE102006024024A patent/DE102006024024A1/de not_active Withdrawn
-
2007
- 2007-05-21 DK DK07725514.9T patent/DK2027096T3/da active
- 2007-05-21 EP EP07725514A patent/EP2027096B8/fr not_active Not-in-force
- 2007-05-21 WO PCT/EP2007/004615 patent/WO2007134862A1/fr not_active Ceased
- 2007-05-21 MX MX2008014797A patent/MX2008014797A/es active IP Right Grant
- 2007-05-21 CA CA2652834A patent/CA2652834C/fr not_active Expired - Fee Related
- 2007-05-21 AU AU2007253572A patent/AU2007253572B9/en not_active Ceased
- 2007-05-21 KR KR1020087031086A patent/KR101426574B1/ko not_active Expired - Fee Related
- 2007-05-21 US US12/301,616 patent/US8084481B2/en not_active Expired - Fee Related
- 2007-05-21 CN CN200780027634.4A patent/CN101495458B/zh not_active Expired - Fee Related
- 2007-05-21 JP JP2009511411A patent/JP5247684B2/ja not_active Expired - Fee Related
- 2007-05-21 RU RU2008150598/04A patent/RU2460724C2/ru not_active IP Right Cessation
- 2007-05-21 PL PL07725514T patent/PL2027096T3/pl unknown
- 2007-05-21 BR BRPI0711975-5A patent/BRPI0711975A2/pt not_active IP Right Cessation
- 2007-05-22 TW TW096118061A patent/TW200817336A/zh unknown
- 2007-05-22 PE PE2007000627A patent/PE20080706A1/es not_active Application Discontinuation
- 2007-05-23 AR ARP070102236A patent/AR061114A1/es not_active Application Discontinuation
- 2007-05-23 PT PT07725514T patent/PT2027096E/pt unknown
- 2007-05-23 ES ES07725514T patent/ES2385606T3/es active Active
- 2007-05-23 DO DO2007000102A patent/DOP2007000102A/es unknown
- 2007-05-24 UY UY30364A patent/UY30364A1/es not_active Application Discontinuation
-
2008
- 2008-11-06 TN TNP2008000443A patent/TNSN08443A1/en unknown
- 2008-11-06 IL IL195142A patent/IL195142A/en not_active IP Right Cessation
- 2008-11-19 ZA ZA2008/09860A patent/ZA200809860B/en unknown
- 2008-11-20 SV SV2008003098A patent/SV2009003098A/es not_active Application Discontinuation
- 2008-11-20 GT GT200800250A patent/GT200800250A/es unknown
- 2008-11-21 HN HN2008001720A patent/HN2008001720A/es unknown
- 2008-11-21 EC EC2008008904A patent/ECSP088904A/es unknown
- 2008-12-05 MA MA31452A patent/MA30500B1/fr unknown
-
2011
- 2011-12-26 US US13/337,216 patent/US20130005704A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5089004B2 (ja) | ボリコナゾールを含有する薬剤製剤 | |
| US6218375B1 (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin and method | |
| EP2539372B1 (fr) | Emulsion acrylique associative contenant un monomere a base d'alcool oxo, son procede de fabrication et procede d'epaississement d'une formulation aqueuse a partir de cette emulsion | |
| JP2005523305A (ja) | フマギロール誘導体又はその塩の包接化合物、及び該包接化合物を含む医薬組成物 | |
| WO2007141344B1 (fr) | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques | |
| CN1272765A (zh) | 一种碘代炔丙基化合物与甲醛供体的稳定化混合物 | |
| EA032006B1 (ru) | Композиции алкилированного циклодекстрина и способы их получения и применения | |
| EP0494554B1 (fr) | Nouveaux copolymères cationiques, de nouvelles émulsions et leur application | |
| JP2003509351A5 (fr) | ||
| US20170246323A1 (en) | Pyrrolidone derivatives, oligomers and polymers | |
| BRPI0715260A2 (pt) | composiÇço aquosa espumÁvel e higienizador de mços | |
| JP2023001833A (ja) | 抗菌性粒子分散体 | |
| RU2013107761A (ru) | Фармацевтическая композиция, содержащая триптофановое производное | |
| ES2210681T3 (es) | Composiciones anatimicrobianas y su utilizacion. | |
| US20100015083A1 (en) | Method of producing pvp/fullerene complex and aqueous solution thereof | |
| JPWO2017188257A1 (ja) | メチル化ポリロタキサンおよびその合成方法 | |
| CN101039620A (zh) | 基于树枝状大分子的组合物及其使用方法 | |
| WO1999050308A1 (fr) | Emulsions eau dans eau, stables et de faible taille de particules, leur procede de synthese et application en tant qu'epaississants | |
| WO2005011704A1 (fr) | Produit contenant de la prostaglandine | |
| JP5148317B2 (ja) | 水性液用ゲル化剤、水性液ゲル及び水性液ゲルの製造方法 | |
| EP1638618A1 (fr) | Composition desinfectante, aqueuse et prete-a-l'emploi d'un complexe stabilise d'acide peracetique, de peroxyde d'hydrogene, de peroxyacides et d'acide acetique | |
| CN1864485A (zh) | 腈菌唑悬浮剂组合物及其生产方法 | |
| Rovers et al. | Controlling Drug Release From Supramolecular Polymer Surfaces by a Click‐To‐Release Reaction | |
| Mozhaev et al. | Stability of α-chymotrypsin conjugated with poly (ethylene glycols) and proxanols at high temperature and in watercosolvent mixtures | |
| FR3113069B1 (fr) | Procede de fabrication de papier et de carton |